Header

UZH-Logo

Maintenance Infos

Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma


Tonder, M; Weller, M; Eisele, G; Roth, P (2014). Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma. Chemotherapy, 60(5-6):375-378.

Abstract

BACKGROUND Treatment of recurrent anaplastic glioma and glioblastoma remains a particular challenge in neurooncology. The lack of controlled trials results in poor evidence for all therapeutic options. Upon recurrence, many patients are treated with bevacizumab or one of the frequently used nitrosoureas such as lomustine. However, patients who still present in overall good condition after failure of multiple lines of therapy may ask for additional therapy. METHODS Here, we report our experience with the use of carboplatin in combination with etoposide as fourth- or fifth-line therapy in patients with progressive high-grade glioma. RESULTS The median Karnofsky performance status at the beginning of treatment was 80%. The median progression-free survival (PFS) was 2.5 months. PFS at 6 months was 0%. Administration of carboplatin and etoposide was associated with grade 3 or 4 hematotoxicity in 8 of 12 patients. CONCLUSION Carboplatin in combination with etoposide has an unfavorable risk-benefit profile in heavily pretreated glioma patients.

Abstract

BACKGROUND Treatment of recurrent anaplastic glioma and glioblastoma remains a particular challenge in neurooncology. The lack of controlled trials results in poor evidence for all therapeutic options. Upon recurrence, many patients are treated with bevacizumab or one of the frequently used nitrosoureas such as lomustine. However, patients who still present in overall good condition after failure of multiple lines of therapy may ask for additional therapy. METHODS Here, we report our experience with the use of carboplatin in combination with etoposide as fourth- or fifth-line therapy in patients with progressive high-grade glioma. RESULTS The median Karnofsky performance status at the beginning of treatment was 80%. The median progression-free survival (PFS) was 2.5 months. PFS at 6 months was 0%. Administration of carboplatin and etoposide was associated with grade 3 or 4 hematotoxicity in 8 of 12 patients. CONCLUSION Carboplatin in combination with etoposide has an unfavorable risk-benefit profile in heavily pretreated glioma patients.

Statistics

Citations

2 citations in Web of Science®
2 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

37 downloads since deposited on 27 Nov 2015
22 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2014
Deposited On:27 Nov 2015 11:49
Last Modified:03 Jun 2016 15:39
Publisher:Karger
ISSN:0009-3157
Additional Information:© 2015 S. Karger AG
Publisher DOI:https://doi.org/10.1159/000440678
PubMed ID:26496463

Download

Download PDF  'Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 66kB
View at publisher
Download PDF  'Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma'.
Preview
Content: Published Version
Filetype: PDF
Size: 397kB